Nicotibine (Isoniazid)

Isoniazid, the active ingredient in Nicotibine, is an antibiotic presented as an oral tablet for oral use. It treats active and latent tuberculosis in adults and children, forming a core component of standard combination regimens recommended by WHO. The tablet contains a precise dose of isoniazid to ensure consistent therapeutic exposure.

GNH USA supplies Nicotibine as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The product conforms to EU quality standards and is manufactured under strict GMP conditions.

Isoniazid is used in the management of tuberculosis, targeting the bacterial infection that causes the disease.

Active tuberculosis: used as part of multi‑drug therapy to eradicate Mycobacterium tuberculosis infection. Latent tuberculosis infection: administered to prevent progression to active disease in individuals with a positive tuberculin test. Tuberculosis prophylaxis in high‑risk contacts: given to reduce the risk of developing active TB after exposure.

Isoniazid may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea or vomiting - Loss of appetite - Abdominal discomfort - Peripheral neuropathy (tingling or numbness) - Skin rash or itching - Mild fever

Serious or Rare Side Effects: - Hepatotoxicity, including severe hepatitis - Stevens‑Johnson syndrome or toxic epidermal necrolysis - Anaphylactic reactions - Seizures (especially in overdose) - Agranulocytosis or severe blood dyscrasias

Before initiating therapy, several safety considerations should be observed.

Liver function monitoring: obtain baseline liver enzymes and repeat periodically during therapy. Alcohol consumption: avoid or limit alcohol intake to reduce hepatotoxic risk. Vitamin B6 supplementation: consider pyridoxine to prevent peripheral neuropathy, especially in patients with risk factors. Pregnancy: use only if potential benefit justifies potential risk to the fetus. Drug interactions: review concomitant medications for hepatic metabolism interactions. Store at ambient temperature: keep tablets in original container, protect from moisture and heat.

Isoniazid can interact with several medicines, requiring caution.

Major Interactions (Avoid): - Rifampicin: increased risk of hepatotoxicity when combined. - Pyrazinamide: additive liver toxicity. - Alcohol: synergistic hepatotoxic effect.

Moderate Interactions (Monitor Closely): - Acetylsalicylic acid: may increase bleeding risk. - Warfarin: may alter INR, requiring closer monitoring.